FDA Approves New Combo Therapy for Melanoma

Share this content:
FDA Approves New Combo Therapy for Melanoma
FDA Approves New Combo Therapy for Melanoma

FRIDAY, Oct. 2, 2015 (HealthDay News) -- A new treatment for melanoma that combines two cancer drugs has been approved by the U.S. Food and Drug Administration. The therapy for advanced melanoma includes the drugs Yervoy (ipilimumab) and Opdivo (nivolumab), the Wall Street Journal reported.

Each medication has a different mechanism of action; both drugs were previously approved individually to treat melanoma.

The new combined treatment will cost more than $250,000 per patient for the first full year of treatment, according to maker Bristol-Myers Squibb. There are concerns that the high cost could prevent some patients from receiving the therapy.

"What we don't want to see is that cost becomes a factor in people getting the best kind of care that's available," Tim Turnham, Ph.D., executive director of the nonprofit Melanoma Research Foundation, told the Wall Street Journal.

Health Highlights: Oct. 2, 2015

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trends in HIV/AIDS Have Worsened in African-Americans

Trends in HIV/AIDS Have Worsened in African-Americans

Action plan developed for community leaders that can reduce the disparity in HIV/AIDS

cfDNA Screening First for Trisomy 21 Doesn't Cut Miscarriage Rate

cfDNA Screening First for Trisomy 21 Doesn't Cut ...

Invasive testing if positive for trisomy 21 on cfDNA screen compared with immediate invasive testing

HPV Legislation Doesn't Impact Teen Sexual Behaviors

HPV Legislation Doesn't Impact Teen Sexual Behaviors

No substantive or significant associations between HPV legislation and adolescent sexual behaviors

is free, fast, and customized just for you!




Already a member?

Sign In Now »